DASATINIB (dasatinib) by Teva is dasatinib, at nanomolar concentrations, inhibits the following kinases: bcr-abl, src family (src, lck, yes, fyn), c-kit, epha2, and pdgfrβ. Approved for older with ph+ cml in chronic phase, newly diagnosed adults with philadelphia chromosome-positive (ph+) chronic myeloid leukemia (cml) in chronic phase, leukemia. First approved in 2025.
Drug data last refreshed 18h ago
Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro , dasatinib was active in leukemic cell lines…
Worked on DASATINIB at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Dasatinib for HIV-1 Reservoir Reduction
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)
Bioequivalence Studies of Dasatinib 100 Mg
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia